Home
Storia in 2 fonti
These 4 charts show the scale of Novo Nordisk's woes
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.
- ·
cnbc.com
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial
Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.
- ·
cincodias.elpais.com
Novo Nordisk vuelve a hundirse en Bolsa al fallar los ensayos de su nuevo medicamento contra la obesidad
La acción cae hasta un 16% y se deja ya un 75% desde mediados de 2024. El grupo danés se queda por detrás de su rival estadounidense Eli Lilly
- ·
Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades
Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its weight loss candidate CagriSema.
- ·
These 4 charts show the scale of Novo Nordisk's woes
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.